Can Amgen Leapfrog A Key Rival And Add Millions Of New Patients?

Biotech giant Amgen (AMGN) could expand the market for Repatha by 4.5 million patients with high cholesterol if the PCSK9 inhibitor proves its mettle in a new study, an analyst said Friday.